Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EP0M
|
|||
| Drug Name |
PMID29334795-Compound-24
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAILEY, James, Matthew BRUTON, Gordon HUXLEY, Anthony MILNER, Peter, Henry ORLEK, Barry, Sidney
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H29N3O
|
|||
| Canonical SMILES |
CC(C)N1CCC(CC1)OC2CCN(CC2)C3=CC=C(C=C3)C#N
|
|||
| InChI |
1S/C20H29N3O/c1-16(2)22-11-7-19(8-12-22)24-20-9-13-23(14-10-20)18-5-3-17(15-21)4-6-18/h3-6,16,19-20H,7-14H2,1-2H3
|
|||
| InChIKey |
RIRWRSQXDDJXDS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Inverse agonist | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.